MEDI 5083

Drug Profile

MEDI 5083

Alternative Names: MEDI5083

Latest Information Update: 21 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Macromolecular substances
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Mar 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Combination therapy) in Australia and USA (NCT03089645)
  • 21 Mar 2017 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in USA, Australia (NCT03089645)
  • 20 Mar 2017 Medimmune plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Combination therapy) in Australia and USA (NCT03089645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top